ImpediMed

ImpediMed OCF/Debt

The Operating Cash Flow to Debt Ratio of ImpediMed (IPD.AX) as of Oct 17, 2026 is -120.70 %. In the previous year, Operating Cash Flow to Debt Ratio was -101.06 % — a change of 19.43% (lower).

OCF/Debt

-120.70 %

YoY

19.43%

Last updated:

Operating Cash Flow to Debt Ratio of ImpediMed is 2026 -120.70 % . Operating Cash Flow to Debt Ratio of ImpediMed was 2025 -101.06 % . It decreases by 19.43% lower compared to the previous year.

The ImpediMed OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2019
-2,248.91 AUD
Jan 1, 2020
-2,206.43 AUD
Jan 1, 2021
-2,797.05 AUD
Jan 1, 2022
-9,214.12 AUD
Jan 1, 2023
-1,247.34 AUD
Jan 1, 2024
-1,556.34 AUD
Jan 1, 2025
-101.06 AUD
Jan 1, 2026
-120.70 AUD
The ImpediMed OCF/Debt history
YEAROCF/DebtYoY
-120.70 %+19.43%
-101.06 %-93.51%
-1,556.34 %+24.77%
-1,247.34 %-86.46%
-9,214.12 %+229.42%
-2,797.05 %+26.77%
-2,206.43 %-1.89%
-2,248.91 %-77.95%
-10,199.13 %-76.86%
-44,079.31 %+43.51%
-30,715.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Operating Cash Flow to Debt Ratio of ImpediMed is -120.70 % in 2026.

Operating Cash Flow to Debt Ratio of ImpediMed changed from -101.06 % to -120.70 %, representing a 19.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio ImpediMed since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's ImpediMed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ImpediMed

All Key Metrics — ImpediMed